Home›Clinical trials›PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Enrolling now · NCT05390892

A study testing whether a GLP-1 medicine from Brigham and Women's Hospital, semaglutide, can lower blood sugar and help with weight.

What this means for you

Who can join
Adults 40 to 80, have type 2 diabetes.
What you take
semaglutide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.
How long it lasts
The full study runs about 6.5 years; your own time in it is usually shorter.
What you get
The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.
Phase Phase 4Sponsor Brigham and Women's HospitalDrug semaglutideClass GLP-1 RASites 36 USEnrollment target 6,000

What this study is for

Primary condition: Type2Diabetes. Also studied in: ASCVD.

Full scientific study title: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes.

Who can join

Age40 to 80SexAny

Adults 40 to 80, have type 2 diabetes. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Type 2 diabetes based on clinical diagnosis
  • HbA1c >=6% measured within 12 months prior to screening
  • Secondary prevention cohort (at least 70% of cohort):
  • Age 40 to 80 years
  • Evidence of established atherosclerotic cardiovascular disease (ASCVD), as defined by one or more of the following

Key exclusion criteria

  • Known or suspected diabetes of other cause (type 1 diabetes, pancreatogenic diabetes, monogenic diabetes, etc.)
  • Any background diabetes medication regimen will be allowed in this pragmatic trial with the following proviso:
  • History of diabetic ketoacidosis
  • Active diabetic foot ulcer
  • History of pancreatitis

Where this study is enrolling

This trial has 36 sites across 25 states. Contact a site coordinator directly to start screening.

Alabama1 site
Arizona1 site
California1 site
Florida2 sites
Georgia2 sites
Illinois2 sites
Iowa1 site
Kansas1 site
  • University of Kansas Medical Center
    Fairway, Kansas
    Erica Lower, CCRP913-588-6052elower@kumc.edu
Maryland3 sites
Massachusetts2 sites
Michigan1 site
Minnesota2 sites
Missouri1 site
Nebraska1 site
  • University of Nebraska Medical Center
    Omaha, Nebraska
    Khadieja M Abuzaho402-559-4815kabuzaho@unmc.edu
New York1 site
  • Naomi Berrie Diabetes Center at New York Presbyterian-Columbia University
    New York, New York
    Angel Suzana212-851-5492precidentd@cumc.columbia.edu
North Carolina2 sites
Ohio1 site
Oregon1 site
Pennsylvania2 sites
Rhode Island1 site
  • Family Care Center at Kent Hospital
    Pawtucket, Rhode Island
    Angela Larkin401-921-9066ALarkin@kentri.org
South Carolina2 sites
  • Medical University of South Carolina
    Charleston, South Carolina
    Audra Wiser(843) 876-9928wisera@musc.edu
  • South Carolina Clinical Research, LLC
    Orangeburg, South Carolina
    Payton Padgett803-531-2220ppadgett@scnephrology.net
Tennessee1 site
Texas2 sites
Virginia1 site
  • Kidney and Hypertension Specialists, PLLC
    Manassas, Virginia
    Hanan Ebjad, MD, MHSA703-361-7341Research@NovaKidney.Com
Wisconsin1 site
  • Medical College of Wisconsin
    Milwaukee, Wisconsin
    Kailie Roth414-805-8104kroth@mcw.edu

Timeline

Started enrolling: 2022-09-26. Expected completion: 2029-03-01. Last updated on ClinicalTrials.gov: 2026-04-13.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact
Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page weekly.